Axsome Therapeutics Presents Positive AXS-07 Phase 1 Trial Results at the 19th Congress of the International Headache SocietyGlobeNewsWire • 09/05/19
Axsome Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare ConferenceGlobeNewsWire • 09/03/19
Axsome Therapeutics, Inc (AXSM) CEO Herriot Tabuteau on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
Here's Why Axsome Therapeutics Stock Rocketed 813% in the First Half of 2019The Motley Fool • 07/07/19
Axsome Shares Rally After FDA OKs Expedited Regulatory Filings For Depression DrugBenzinga • 05/06/19
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab FlopThe Motley Fool • 03/30/19